Incyte Corporation (INCY)

[surf1944]

1:40AM Incyte presents final results from a Phase I trial of INCB024360 (INCY) 22.17 : Co announces final results today from the Phase I clinical trial for its oral indoleamine dioxygenase-1 inhibitor. The key findings of the study include:

Data demonstrate that INCB024360 achieves greater than 90% inhibition of IDO1 at generally well-tolerated doses and may represent a new treatment option for advanced malignancies
Data suggest the potential for INCB024360 to be used as monotherapy or in combination with other cancer agents
The most common grade 1 or 2 adverse events were fatigue and gastrointestinal disturbances, and the most common grade 3 or 4 adverse events were abdominal pain, hypokalemia and fatigue